Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
Hundreds of patients are suing manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, alleging the drugs caused permanent vision loss. The litigation specifically links these weight-loss and diabetes medications to non-arteritic anterior ischemic optic neuropathy, a rare condition described as an eye stroke. Plaintiffs claim the drugs triggered sudden sight loss, leading to numerous legal filings against the pharmaceutical companies. While the condition is rare, the volume of lawsuits suggests a growing pattern of reported ocular complications among users of these popular medications.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Hundreds of lawsuits allege GLP-1 medications caused vision loss.
- ✓ Litigation targets manufacturers of drugs including Ozempic, Wegovy, Mounjaro, and Zepbound.
- ✓ The lawsuits link these medications to non-arteritic anterior ischemic optic neuropathy.
- ✓ Plaintiffs allege the drugs caused permanent vision loss.
What changed
Legal filings now explicitly name non-arteritic anterior ischemic optic neuropathy as the cause of vision loss.
Live updates
-
Hundreds of lawsuits link GLP-1 drugs to permanent vision loss
Hundreds of patients are suing manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, alleging the drugs caused permanent vision loss. The litigation specifically links these weight-loss and diabetes medications to non-arteritic anterior ischemic optic neuropathy, a rare condition described as an eye stroke. Plaintiffs claim the drugs triggered sudden sight loss, leading to numerous legal filings against the pharmaceutical companies. While the condition is rare, the volume of lawsuits suggests a growing pattern of reported ocular complications among users of these popular medications.
Why it matters
GLP-1 receptor agonists are widely prescribed for type 2 diabetes and weight management. These lawsuits focus on the potential for severe, irreversible neurological damage to the optic nerve. The legal outcome will determine if manufacturers failed to warn patients about these specific ocular risks.
What is confirmed
- Hundreds of lawsuits allege GLP-1 medications caused vision loss.
- Litigation targets manufacturers of drugs including Ozempic, Wegovy, Mounjaro, and Zepbound.
- The lawsuits link these medications to non-arteritic anterior ischemic optic neuropathy.
- Plaintiffs allege the drugs caused permanent vision loss.
What to watch next
- Court rulings on whether manufacturers provided adequate warnings about optic neuropathy
- Clinical studies confirming a causal link between GLP-1 drugs and eye strokes
- Responses from pharmaceutical companies regarding the specific medical claims
confidence 95%Sources used for this update (9)
- USA Today — Are GLP-1s causing blindness? What we know about rare cases
- NewsNation — Patients sue GLP-1 makers over sudden loss of vision
- ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
- WSOC TV — Patients sue GLP-1 makers over risk of blindness
- Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
- AZ Family — Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
- TODAY.com — Woman Details Losing Vision After Taking GLP-1 As Hundreds of Patients Sue Drug Companies
- www.wmur.com — Some GLP-1 companies facing lawsuits over rare condition causing vision loss
- www.yahoo.com — Lawsuits claim popular GLP-1 drugs linked to vision loss
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community